Osterweis Capital Management Inc. Reduces Stake in Boston Scientific Corporation $BSX

Key Points

• Osterweis Capital Management Inc. reduced its stake in Boston Scientific Corporation by 15.7%, selling 52,069 shares, leaving them with 279,343 shares valued at approximately $28.18 million.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, surpassing analysts' estimates, with revenue of $5.06 billion, marking a 22.8% increase year-over-year.
• Institutional investors currently hold 89.07% of Boston Scientific's stock, indicating strong interest from larger investment entities in the company's performance.

Osterweis Capital Management Inc. reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 15.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 279,343 shares of the medical equipment provider's stock after selling 52,069 shares during the quarter. Osterweis Capital Management Inc.'s holdings in Boston Scientific were worth $28,180,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. HM Payson & Co. increased its position in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares in the last quarter. Baldwin Investment Management LLC increased its position in shares of Boston Scientific by 1.2% in the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after buying an additional 102 shares in the last quarter. Park Square Financial Group LLC increased its position in shares of Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC increased its position in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after buying an additional 103 shares in the last quarter. Finally, Forum Financial Management LP increased its position in shares of Boston Scientific by 0.8% in the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after buying an additional 112 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer owned 1,476,882 shares in the company, valued at $153,137,894.58. This represents a 10.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 in the last quarter. Insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on BSX shares. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Citigroup restated a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Truist Financial boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Wells Fargo & Company boosted their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Finally, Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Trading Down 0.2%

Shares of Boston Scientific stock traded down $0.1630 during trading hours on Monday, hitting $106.0070. The company's stock had a trading volume of 1,558,830 shares, compared to its average volume of 7,530,821. The firm has a fifty day moving average of $104.10 and a 200-day moving average of $102.12. Boston Scientific Corporation has a twelve month low of $78.90 and a twelve month high of $108.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $157.08 billion, a price-to-earnings ratio of 63.12, a P/E/G ratio of 2.56 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 EPS. Boston Scientific's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.